“Targeting OX40 With GBR 830, An OX40 Antagonist, Inhibits T Cell-Mediated Pathological Responses”. SKIN The Journal of Cutaneous Medicine 2 (December 17, 2018): S62. Accessed October 6, 2025. https://skin.dermsquared.com/skin/article/view/458.